Angelini Ventures — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Cadence Neurosciencecadenceneuro.cominMay 2023 · $26M
Cadence develops a neuromodulation system intended to be a more effective, less invasive treatment for people living with drug-refractory epilepsy.
BiotechDigital HealthHealthtechMedical DevicesSammamish, US
Kent Leyde(Executive Officer, Director, Promoter)Warren Douglas Sheffield(Executive Officer, Director, Promoter)
Co-investorsJAZZ Venture PartnersLumira VenturesF-Prime CapitalIaso Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.